These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16776749)

  • 21. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).
    Cvetković RS; Plosker GL
    Drugs; 2007; 67(6):935-54. PubMed ID: 17428109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
    J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
    Henry RR; Rosenstock J; Logan D; Alessi T; Luskey K; Baron MA
    J Diabetes Complications; 2014; 28(3):393-8. PubMed ID: 24631129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exenatide: new drug. Type 2 diabetes for some overweight patients.
    Prescrire Int; 2007 Dec; 16(92):228-31. PubMed ID: 18087791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
    Malloy J; Meloni A; Han J
    Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
    Buse JB; Henry RR; Han J; Kim DD; Fineman MS; Baron AD;
    Diabetes Care; 2004 Nov; 27(11):2628-35. PubMed ID: 15504997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA
    Henry RR; Rosenstock J; Denham DS; Prabhakar P; Kjems L; Baron MA
    Diabetes Care; 2018 Mar; 41(3):613-619. PubMed ID: 29301824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.
    Quan H; Zhang H; Wei W; Fang T
    J Diabetes Complications; 2016; 30(4):686-92. PubMed ID: 26873871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.
    Abdul-Ghani MA; Puckett C; Triplitt C; Maggs D; Adams J; Cersosimo E; DeFronzo RA
    Diabetes Obes Metab; 2015 Mar; 17(3):268-75. PubMed ID: 25425451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
    Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
    Rosenstock J; Rood J; Cobitz A; Huang C; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):643-9. PubMed ID: 17026488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
    Pujante Alarcón P; Hellín Gil MD; Román LM; Ferrer Gómez M; García Zafra MV; Tébar Massó J
    Med Clin (Barc); 2012 Dec; 139(13):572-8. PubMed ID: 22209597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.
    Henry RR; Klein EJ; Han J; Iqbal N
    Diabetes Technol Ther; 2016 Nov; 18(11):677-686. PubMed ID: 27525540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
    Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
    Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
    Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of exenatide in poorly controlled type 2 diabetes.
    Kaimal N; Schofield J; Zaki A; Patel R; Sharma M; McCourt E; Imtiaz KE
    QJM; 2012 Apr; 105(4):321-6. PubMed ID: 22056400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
    Bergenstal RM; Li Y; Porter TK; Weaver C; Han J
    Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.